AR048030A1 - Una vacuna canina para proteccion contra erliquiosis - Google Patents

Una vacuna canina para proteccion contra erliquiosis

Info

Publication number
AR048030A1
AR048030A1 ARP050100919A ARP050100919A AR048030A1 AR 048030 A1 AR048030 A1 AR 048030A1 AR P050100919 A ARP050100919 A AR P050100919A AR P050100919 A ARP050100919 A AR P050100919A AR 048030 A1 AR048030 A1 AR 048030A1
Authority
AR
Argentina
Prior art keywords
virulent
ehrlichia canis
erliquiosis
canine
induces
Prior art date
Application number
ARP050100919A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR048030A1 publication Critical patent/AR048030A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion de una vacuna segura y eficaz que comprende: una cantidad inmunizadora eficaz de una bacteria de Ehrlichia canis inactivada; un portador farmacologicamente aceptable; y una cantidad inmunogénicamente estimuladora de un sistema auxiliar que consiste esencialmente en un agente inductor de una respuesta de anticuerpos y un agente inductor de una respuesta de inmunidad intermediada por células. Un método para la prevencion o alivio de erliquiosis canina en perros. Reivindicacion 18: Un método para la induccion de erliquiosis canina clínica en un animal de ensayo que comprende administrar a dicho animal de ensayo una cantidad eficaz de una carga de provocacion que consiste esencialmente en células mononucleares de sangre periférica infectadas con un microorganismo virulento de Ehrlichia canis virulento. Reivindicacion 22: Una composicion de una carga de provocacion que comprende células mononucleares de sangre periférica infectadas con un microorganismo virulento de Ehrlichia canis.
ARP050100919A 2004-03-11 2005-03-10 Una vacuna canina para proteccion contra erliquiosis AR048030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55235004P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
AR048030A1 true AR048030A1 (es) 2006-03-22

Family

ID=34965712

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100919A AR048030A1 (es) 2004-03-11 2005-03-10 Una vacuna canina para proteccion contra erliquiosis

Country Status (22)

Country Link
US (2) US20050202046A1 (es)
EP (2) EP1723170B1 (es)
JP (1) JP2008500962A (es)
KR (1) KR20060129475A (es)
CN (1) CN1930185A (es)
AR (1) AR048030A1 (es)
AT (1) ATE530566T1 (es)
AU (1) AU2005222396A1 (es)
BR (1) BRPI0508655A (es)
CA (1) CA2558047A1 (es)
CO (1) CO5721012A2 (es)
CY (1) CY1112120T1 (es)
DK (1) DK1723170T3 (es)
ES (1) ES2374278T3 (es)
IL (1) IL177860A0 (es)
ME (1) ME01252B (es)
PL (1) PL1723170T3 (es)
PT (1) PT1723170E (es)
RS (1) RS52188B (es)
SI (1) SI1723170T1 (es)
WO (1) WO2005087803A1 (es)
ZA (1) ZA200607547B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115840A1 (en) * 1998-11-30 2002-08-22 Walker David H. Homologous 28-kilodaltion immunodominant protein genes of Ehrlichia canis and uses thereof
UA99719C2 (ru) * 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
HUE031617T2 (en) 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and preparations for live attenuated viruses
PT2187958T (pt) 2007-09-11 2017-03-17 Yissum Res Dev Company Of The Hebrew Univ Of Jerusalem Vacina atenuada de erliquiose
MX2010002730A (es) 2007-09-12 2010-03-31 Intervet Int Bv Metodos para cultivar especies bacterianos de la familia anaplasmataceae.
US9051557B2 (en) * 2007-09-12 2015-06-09 Intervet International B.V. Method for continuously culturing Ehrlichia canis
EP2045816A1 (en) * 2007-10-01 2009-04-08 Paul Scherrer Institut Fast readout method and swiched capacitor array circuitry for waveform digitizing
CN103200960B (zh) * 2010-07-02 2019-04-23 英特维特国际股份有限公司 针对犬埃利希体的疫苗和相关方法
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
US9651546B2 (en) 2012-10-11 2017-05-16 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US9442112B2 (en) * 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
BR112020001014A2 (pt) * 2017-07-31 2020-07-14 Kansas State University Research Foundation vacinas contra doenças transmitidas por carrapatos
US11046734B2 (en) 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides
US20220356231A1 (en) * 2019-07-12 2022-11-10 Research Development Foundation Ehrlichia vaccines and immunogenic compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192679A (en) * 1990-05-03 1993-03-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Growing ehrlichia species in a continuous cell line
ES2149759T3 (es) * 1990-07-06 2000-11-16 American Home Prod Vacuna contra la enfermedad de lyme.
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
AU7208698A (en) * 1997-03-24 1998-10-20 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
US6043085A (en) 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
US6432649B1 (en) 2000-08-25 2002-08-13 The Ohio State University Research Foundation Methods for detecting Ehrlichia canis and Ehrlichia chaffeensis in vertebrate and invertebrate hosts
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant

Also Published As

Publication number Publication date
EP1723170B1 (en) 2011-10-26
EP2338903A1 (en) 2011-06-29
AU2005222396A1 (en) 2005-09-22
CY1112120T1 (el) 2015-11-04
US20060188524A1 (en) 2006-08-24
CO5721012A2 (es) 2007-01-31
EP1723170A1 (en) 2006-11-22
CN1930185A (zh) 2007-03-14
ZA200607547B (en) 2008-06-25
IL177860A0 (en) 2006-12-31
ME01252B (me) 2013-06-20
JP2008500962A (ja) 2008-01-17
ATE530566T1 (de) 2011-11-15
PL1723170T3 (pl) 2012-03-30
US7635481B2 (en) 2009-12-22
BRPI0508655A (pt) 2007-08-14
SI1723170T1 (sl) 2012-01-31
RS52188B (en) 2012-10-31
DK1723170T3 (da) 2011-12-05
US20050202046A1 (en) 2005-09-15
ES2374278T3 (es) 2012-02-15
WO2005087803A1 (en) 2005-09-22
CA2558047A1 (en) 2005-09-22
KR20060129475A (ko) 2006-12-15
PT1723170E (pt) 2012-01-10

Similar Documents

Publication Publication Date Title
AR048030A1 (es) Una vacuna canina para proteccion contra erliquiosis
Dantas-Torres Leishmune® vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine
Sabaté et al. A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area
World Health Organization WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies
Moriello Treatment of dermatophytosis in dogs and cats: review of published studies
ES2585810T3 (es) Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
Kreiss et al. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations
Sanches et al. The role of immunity and seasonality in cholera epidemics
ECSP034823A (es) Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico
AR066405A1 (es) Vacuna
BRPI0518091A2 (pt) mycobacterium, mÉtodo para permitir com que uma mycobacterium escape a partir de endossomos e preparaÇço para uma vacina
SG163598A1 (en) Lawsonia vaccine and methods of use thereof
EP2712625A3 (en) Vaccines comprising TB 10.4
Basso et al. Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi
BRPI0010418B8 (pt) microorganismo de salmonella, composição de vacina e uso do referido microorganismo.
Kobe et al. A game-theoretic model of cholera with optimal personal protection strategies
ITMI20031617A1 (it) Microcapsule a doppio strato di polisaccaridi utilizzabili
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
Brown et al. Immunogenicity and efficacy of two rabies vaccines in wild-caught, captive raccoons
Knobel et al. Seroconversion in captive African wild dogs (Lycaon pictus) following administration of a chicken head bait/SAG-2 oral rabies vaccine combination
Stein et al. Evaluating temperature sensitivity of vesicular stomatitis virus–based vaccines
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
Schetters et al. Immunity against Babesia rossi infection in dogs vaccinated with antigens from culture supernatants
Spilki et al. Partial Protection Induced by a BHV‐1 Recombinant Vaccine against Challenge with BHV‐5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal